Diabetes should be focus of healthcare professionals year-round
WHAT IT MEANS AND WHY IT’S IMPORTANT There are many pharmacy retailers hooking their diabetes-related initiatives into the awareness generated by American Diabetes Month, but judging by a new study recently issued by the Centers for Disease Control and Prevention, it may be time for healthcare professionals to begin piecing together initiatives that will help maintain that heightened awareness over the course of an entire year.
(THE NEWS: Supervalu encourages healthy lifestyles with diabetes program. For the full story, click here)
That study, published in Population Health Metrics, projected that newly diagnosed cases of diabetes incidence will increase from the eight cases per 1,000 people diagnosed in 2008 to about 15 cases per 1,000 people in 2050. That alone suggests more people will be in need of year-round nutrition programs, such as Supervalu’s “living healthy with my diabetes.” But if those projected increases in diabetes incidence are coupled with a decline in diabetes-related mortality rates, the CDC suggested that as many as 1-in-3 Americans will have diabetes by 2050, as compared with the 1-in-5 Americans who have diabetes today.
Rite Aid posts same-store sales decline
CAMP HILL, Pa. Rite Aid on Thursday posted a same-store sales decrease of 1.7% for the four weeks ended Oct. 23, representing a front-end comparable sales decline of 1.3% and a 1.8% drop in same-store pharmacy sales.
Prescriptions filled at comparable stores decreased 1.9% over the prior-year period.
Both front-end and pharmacy same-store sales were negatively impacted by a significantly weaker cough, cold and flu season compared with the same period last year, when news of an H1N1 pandemic was dominating the airwaves.
Total drug store sales for the four-week period decreased 2.7% to $1.9 billion. Prescription revenue accounted for 68.5% of drug store sales, and third-party prescription revenue represented 96.2% of pharmacy sales.
GSK Consumer Healthcare applauds FDA’s workshop on NRT products
PARSIPPANY, N.J. GlaxoSmithKline Consumer Healthcare on Thursday commended the Food and Drug Administration for holding a scientific workshop this week that focused on the risks and benefits associated with the long-term use of nicotine-replacement therapy products.
GSK, the manufacturer of smoking-cessation products NicoDerm and Nicorette, suggested the workshop is a first step in supporting language in the 2009 Family Smoking Prevention and Tobacco Control Act, which called upon the FDA to "consider approving the extended use of nicotine-replacement products — such as nicotine patches, nicotine gum and nicotine lozenge — for the treatment of tobacco dependence."
As a result of the FDA’s review of long-term use, GSK has submitted a statement into the FDA public docket on its position regarding the long-term use of NRT. GSK believes that using NRT products to quit smoking is far safer than continuing to smoke. NRT products offer a step-down therapy that doubles a smoker’s chances of quitting versus attempting to quit smoking “cold turkey.” Additionally, several other countries already encourage the use of NRT products for longer durations to keep people tobacco-free.
Smoking is the No. 1 preventable cause of disease and death in the United States. More than 46 million Americans smoke. Research indicated about 70% of smokers want to quit at any given time, but the success rates remain suboptimal. Tobacco use causes more than 400,000 deaths in the United States each year, and approximately 8.6 million Americans have chronic illnesses related to smoking.